When we discuss trial participation with patients, we stress that the goal of these studies is to obtain better visual outcomes and ease the treatment burden.
Pamela Ann Weber, MD
Advertisement
Articles by Pamela Ann Weber, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Modern Retina
1
FLORetina 2025: AI at the forefront of ROP care
2
FLORetina 2025: Fibrosis, a limiting factor in visual acuity outcomes in neovascular AMD
3
Prevent Blindness delegates first week of December as 5th annual geographic atrophy week
4
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
5
